risperidone has been researched along with Combat Disorders in 8 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Combat Disorders: Neurotic reactions to unusual, severe, or overwhelming military stress.
| Excerpt | Relevance | Reference |
|---|---|---|
| "DSM-IV PTSD diagnoses were made by using the Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Nonpatient Edition." | 2.82 | Sleep disturbance in chronic military-related PTSD: clinical impact and response to adjunctive risperidone in the Veterans Affairs cooperative study #504. ( Collins, J; Cramer, JA; Huang, GD; Jones, KM; Krystal, AD; Krystal, JH; Pietrzak, RH; Rosenheck, RA; Vertrees, JE; Vessicchio, J, 2016) |
| "T-tests showed that the PTSD sample had more severe symptoms on the Depressive factor, and the schizophrenia sample on the Positive, Negative, and Disorganized factors, with no significant difference on the Excited factor." | 2.79 | Symptom structure and severity: a comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia. ( Krystal, JH; Rosenheck, RA; Stefanovics, EA, 2014) |
| "Treatment with risperidone for either 3 or 6 weeks in an open trial significantly reduced total and subscales scores on the PANSS and on the PTSD-I and CGI-S when compared to baseline scores in patients with psychotic PTSD." | 2.71 | Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. ( Kozarić-Kovacić, D; Mück-Seler, D; Pivac, N; Rothbaum, BO, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stefanovics, EA | 1 |
| Krystal, JH | 2 |
| Rosenheck, RA | 2 |
| Pietrzak, RH | 1 |
| Cramer, JA | 1 |
| Vessicchio, J | 1 |
| Jones, KM | 1 |
| Huang, GD | 1 |
| Vertrees, JE | 1 |
| Collins, J | 1 |
| Krystal, AD | 1 |
| Khachiyants, N | 2 |
| Ali, R | 2 |
| Kovesdy, CP | 1 |
| Detweiler, JG | 2 |
| Kim, KY | 2 |
| Detweiler, MB | 2 |
| David, D | 2 |
| De Faria, L | 2 |
| Lapeyra, O | 1 |
| Mellman, TA | 2 |
| Kozarić-Kovacić, D | 1 |
| Pivac, N | 1 |
| Mück-Seler, D | 1 |
| Rothbaum, BO | 1 |
| Monnelly, EP | 1 |
| Ciraulo, DA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CSP #504 - Risperidone Treatment for Military Service Related Chronic Post-Traumatic Stress Disorder[NCT00099983] | Phase 2 | 296 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Characterization of the Use of Antipsychotics in PTSD During the Past Seven Years[NCT00230893] | 99 participants | Observational | 2005-07-31 | Completed | |||
| Characterization of the Use of Antipsychotics in Posttraumatic Stress Disorder During the Past Decade[NCT00233467] | 0 participants (Actual) | Observational | 2005-09-01 | Withdrawn (stopped due to Funding expired; no subjects enrolled as this was a retrospective chart review) | |||
| A Double-Blind, Placebo-Controlled Random Order Crossover Study of Iloperidone for Symptoms of Arousal in PTSD Including Insomnia and Irritability.[NCT01917318] | Phase 2 | 1 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to Enrollment challenges - Single participant discontinued after placebo, no relevant outcome measure data was recorded.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome measure for this study was the total score on the 34-item Clinician-Administered PTSD Scale (CAPS). This study was the intent-to-treat analysis of the improvement in PTSD symptoms from baseline to week-24 follow-up as measured by the CAPS. Total score range for the CAPS is 0-136 with higher values representing a worse outcome. This study was powered initially to detect a 9-point difference between the treatment groups in the CAPS change score. (NCT00099983)
Timeframe: 24 Weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Risperidone | -16.3 |
| Sugar Pill | -12.5 |
"Intensity of Suicidal Ideation was monitored over the course of the trial by the second section of the Columbia Suicide Severity Rating Scale (CSSRS). This section is only administered if the patient answers yes to the first section. The section consists of 5 questions that refer to the most severe level of ideation endorsed in the first section of the CSSRS. The total score ranges from 2 to 25, with a higher number indicating more intense ideation and greater risk.~Only lifetime intensity of suicidal ideation was explored as the patient had no suicidal ideation from the month prior to beginning the study to the completion of the study" (NCT01917318)
Timeframe: Baseline
| Intervention | score on a scale (Number) |
|---|---|
| Placebo / Iloperidone | 16 |
Aggression was measured by the Modified Overt Aggression Scale (MOAS).This assessment measures four types of aggressive behavior (verbal, aggression against property, autoaggression, and physical aggression) . Total scores on the MOAS range from 0-40, with a higher score indicating more aggressive behavior. (NCT01917318)
Timeframe: Randomization and 8 weeks of treatment, during both treatment periods
| Intervention | units on a scale (Number) | |||
|---|---|---|---|---|
| MOAS at randomization 1 | MOAS after 8 weeks with placebo | MOAS at randomization 2 | MOAS after 2 weeks with iloperidone treatment | |
| Placebo / Iloperidone | 1 | 0 | 0 | 0 |
"The Clinician-Administered PTSD Scale (CAPS) is a structured interview used to diagnose and assess PTSD. Part B of CAPS evaluates symptoms of re-experiencing. Part D evaluates avoidance and numbing.~CAPS-B scores range from 0 to 40 where higher scores indicate more symptoms. A score 0 means no re-experiencing symptoms.~CAPS-D scores range form 0 to 56 and higher scores indicate more symptoms. A score 0 means no avoidance or numbing symptoms.~The primary endpoint was changes in CAPS part B and D after 8 weeks of treatment." (NCT01917318)
Timeframe: Randomization and at the end of each treatment period. Placebo treatment lasted 8 weeks. Iloperidone treatment lasted 2 weeks.
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| CAPS part B at randomization 1 | CAPS part B after 8 weeks with placebo | CAPS part B at randomization 2 | CAPS part B after 2 weeks with iloperidone | CAPS part D at randomization 1 | CAPS part D after 8 weeks with placebo | CAPS part D at randomization 2 | CAPS part D after 2 weeks with iloperidone | |
| Placebo / Iloperidone | 20 | 4 | 4 | 0 | 6 | 2 | 7 | 0 |
The presence and severity os suicidal behavior was monitored over the course of the trial by the third section of the Columbia Suicide Severity Rating Scale (CSSRS). This sections consists of questions about 5 suicidal behaviors and non-suicidal self injurious behavior and it can be answered yes or no. The number of participants who experienced suicidal behavior is reported. (NCT01917318)
Timeframe: Total course of the study. CSSRS was administered during each study visit. Suicidal ideation during lifetime and during the month prior to screening were also explored
| Intervention | participants (Number) | ||
|---|---|---|---|
| Lifetime suicidal behavior | 1 month prior ro screening | During the course of the study | |
| Placebo / Iloperidone | 0 | 0 | 0 |
The presence of suicidal ideation was monitored over the course of the trial by the first section of the Columbia Suicide Severity Rating Scale (CSSRS). This first section of the scale consists of 5 questions that can be answered yes or no. The number of participants who reported experiencing suicidal ideation is reported. (NCT01917318)
Timeframe: Total course of the study. CSSRS was administered during each study visit. Suicidal ideation during lifetime and during the month prior to screening were also explored
| Intervention | participants (Number) | ||
|---|---|---|---|
| Lifetime suicidal ideation | 1 month prior to screening | Suicidal ideation during the study | |
| Placebo / Iloperidone | 1 | 0 | 0 |
4 trials available for risperidone and Combat Disorders
| Article | Year |
|---|---|
Symptom structure and severity: a comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Chronic Disease; Combat Disorders; Diagnosis, | 2014 |
Sleep disturbance in chronic military-related PTSD: clinical impact and response to adjunctive risperidone in the Veterans Affairs cooperative study #504.
Topics: Adult; Aged; Combat Disorders; Double-Blind Method; Female; Humans; Interview, Psychological; Male; | 2016 |
Adjunctive risperidone treatment in combat veterans with chronic PTSD.
Topics: Antipsychotic Agents; Chronic Disease; Combat Disorders; Drug Therapy, Combination; Humans; Male; Mi | 2004 |
Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Combat Disorders; Croa | 2005 |
Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Combat Disorders; Croa | 2005 |
Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Combat Disorders; Croa | 2005 |
Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Combat Disorders; Croa | 2005 |
4 other studies available for risperidone and Combat Disorders
| Article | Year |
|---|---|
Effectiveness of risperidone for the treatment of nightmares in veterans with posttraumatic stress disorder.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Combat Disorders; Dreams; Female; Humans; Male | 2010 |
Risperidone for post-traumatic combat nightmares: a report of four cases.
Topics: Adult; Aged; Antipsychotic Agents; Combat Disorders; Dreams; Humans; Male; Middle Aged; Risperidone; | 2011 |
Adjunctive risperidone treatment and sleep symptoms in combat veterans with chronic PTSD.
Topics: Aged; Antipsychotic Agents; Chronic Disease; Combat Disorders; Drug Therapy, Combination; Dyssomnias | 2006 |
Risperidone effects on irritable aggression in posttraumatic stress disorder.
Topics: Aggression; Anger; Antipsychotic Agents; Combat Disorders; Dose-Response Relationship, Drug; Humans; | 1999 |